HDAC inhibitors: a 2013–2017 patent survey

References

• Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487–500.
   PubMed Web of Science ®Google Scholar
• Archin NM, Keedy KS, Espeseth A, et al. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. Aids. 2009;23(14):1799–1806.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–691.
   PubMed Web of Science ®Google Scholar
• Kee HJ, Kook H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol. 2011;2011:928326.
   PubMedGoogle Scholar
• Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem. 2010;45(6):2095–2116.
   PubMed Web of Science ®Google Scholar
• Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem. 2016;4(121):451–483.
   Google Scholar
• Kozikowski A, Gaisina I Preparation of HDAC inhibitors and therapeutic methods using the same. WO2017040564A1, 2017.
   Google Scholar
• Jarpe MB, Benoy V, Helleputte LV, et al. Preparation of pyrimidine hydroxy amides as selective HDAC6 inhibitors for the treatment of peripheral neuropathy. WO2016090230A1, 2016.
   Google Scholar
• Yang M, Tamang DL, Jones SS Preparation of pyrimidine hydroxy amide compounds as histone deacetylase inhibitors. WO2015054474A1, 2015.
   Google Scholar
• Dominguez C, Munoz-Sanjuan I, Maillard M, et al. Histone deacetylase inhibitors and compositions and methods of use thereof. WO2014159214A1, 2014.
   Google Scholar
• Chern J-W, Yu C-W, Chang P-T Preparation of substituted quinazolinones as histone deacetylases (HDACs) inhibitors. US20130267542A1, 2013.
   Google Scholar
• Zheng X, Ng YP, Han B, et al. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors. 2016126725, 2016.
   Google Scholar
• Zheng X, Ng PY, Han B, et al. 3-Aryl-4-amidobicyclic[4,5,0] hydroxamic acid as HDAC inhibitors and their preparation. US20160222022A1, 2016.
   Google Scholar
• Zheng X, Ng PY, Rudnitskaya A, et al. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors and their preparation. US20160221997A1, 2016.
   Google Scholar
• Ng PY, Davis H, Bair KW, et al. Preparation of 3-spiro-7-hydroxamic acid tetralins as histone deacetylase inhibitors. WO2016168660A1, 2016.
   Google Scholar
• Edderkaoui M, Murali R, Pandol S HDAC/GSK3β dual inhibitor compositions and methods for treating cancers. WO2015192078A1, 2015.
   Google Scholar
• Shuttleworth SJ, Tomassi CD, Cecil ARL, et al. Heteroarylamines as histone deacetylase inhibitors and their preparation and use for the treatment of HDAC-mediated diseases.. WO2014181137A1, 2014.
   Google Scholar
• Shuttleworth SJ, Cecil ARL, MacCormick S, et al. Polyheteroaryls, especially 4-[[(heteroaryl)(biheteroaryl)amino]methyl]-N-hydroxybenzamide derivatives, as histone deacetylase inhibitors and their preparation and use for the treatment of HDAC-mediated diseases. WO2016067038A1, 2016.
   Google Scholar
• Lee C, Yang H-M, Choi H, et al. Preparation of novel urea derivatives as selective histone deacetylase inhibitors. WO2014178606A1, 2014.
   Google Scholar
• Breslow R, Marks PA Preparation of novel hydroxamates that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1. WO2013052110A1, 2013.
   Google Scholar
• Mahboobi S, Sellmer A, Pongratz H, et al. Preparation of fused heterocyclic compounds as HDAC6 inhibitors and their uses. WO2016020369A1, 2016.
   Google Scholar
• Lee C, Yang H-M, Lee C, et al. Preparation of novel azaindole derivatives as selective histone deacetylase (HDAC) inhibitors. WO2015087151A1, 2015.
   Google Scholar
• Ma H, Wang Y Preparation of histone deacetylase (HDAC) inhibitors and methods for use thereof. US20170044185A1, 2017.
   Google Scholar
• Kozikowski A, Shen S, Bergman J Preparation of tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors. WO2017142883A1, 2017.
   Google Scholar
• Hoepfner M, Biersack B, Schobert R, et al. 4,5-Diarylimidazole derivatives as HDAC inhibitors. WO2016008836A1, 2016.
   Google Scholar
• Chen Y, Chen Y Aminobenzimidazole derivatives as HDAC inhibitor and their preparation and use in the treatment of neoplastic and immune diseases. WO2013113838A1, 2013.
   Google Scholar
• Hooker JM, Wang C, Schroeder FA Preparation of substituted hydroxamic acids as histone deacetylase inhibitors. WO2016018795A1, 2016.
   Google Scholar
• Oyelere AK, Tapadar S, Gaul D Preparation of cyanonilutamidebenzylhydroxyacrylamide derivatives for use as HDAC inhibitors. WO2017120328A1, 2017.
   Google Scholar
• Alami M, Hamze A, Brion J-D, et al. Multi-target antitumor compounds with histone deacetylase-inhibitory activity with inhibitory activity on tubulin polymerization. WO2017118822A2, 2017.
   Google Scholar
• Pan J, Wang X, Barbosa J, et al. Preparation of heterocyclic compounds as HDAC modulators. WO2017030938A1, 2017.
   Google Scholar
• Shuttleworth SJ, Cecil ARL, MacCormick S, et al. Diheteroaryls as histone deacetylase inhibitors and their preparation and use for the treatment of HDAC-mediated diseases. WO2016067040A1, 2016.
   Google Scholar
• Shuttleworth SJ, Tomassi CD, Cecil ARL, et al. Preparation of N-hydroxypyridinylaminoalkanamide compounds as histone deacetylase inhibitors and their use in therapy. WO2014072714A1, 2014.
   Google Scholar
• Lee C, Lee J, Song H, et al. Preparation of heterocyclic-alkyl compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same. WO2016190630A1, 2016.
   Google Scholar
• Grindrod S, Jung M, Brown M, et al. Preparation of dual function indole derivatives for histone deacetylase inhibition and ataxia telangiectasia mutated activation. WO2016141122A1, 2016.
   Google Scholar
• Wang H, Chen D, Soh CK Preparation of fused pyrimidine-based hydroxamate derivatives as inhibitors of histone deacetylase (HDAC) and kinases. WO2015137887A1, 2015.
   Google Scholar
• Liu X, Zhang G, Chan DC-F, et al. Preparation of heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof. WO2015175813A1, 2015.
   Google Scholar
• Giannini G, Battistuzzi G, Vignola D, et al. Preparation of hydroxamate derivatives bearing amide-lactams as potent HDAC inhibitors and their uses as medicaments. WO2014122222A1, 2014.
   Google Scholar
• Dominguez C, Munoz-Sanjuan I, Beaumont V, et al. Histone deacetylase inhibitors and compositions and methods of use thereof. WO2014159210A1, 2014.
   Google Scholar
• Dominguez C, Luckhurst CA, Burli RW, et al. Histone deacetylase inhibitors and compositions and methods of use thereof. WO2014014900A1, 2014.
   Google Scholar
• Dominguez C, Munoz-Sanjuan I, Luckhurst CA, et al. Preparation of fused bicyclic compounds as histone deacetylase inhibitors. WO2015187542A1, 2015.
   Google Scholar
• Dominguez C, Munoz-Sanjuan I, Maillard M, et al. Preparation of histone deacetylase inhibitors. WO2014159218A1, 2014.
   Google Scholar
• Hukriede N, Bw D, McDermott LA. Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury and their preparation. WO2014071000A1, 2014.
   Google Scholar
• Kovach JS HDAC inhibitors for treating traumatic brain injury. WO2014137741A1, 2014.
   Google Scholar
• Jacques V, Rusche JR, Peet NP, et al. N-Aminophenyl benzamide derivatives as histone deacetylase inhibitors and their preparation. WO2014152444A1, 2014.
   Google Scholar
• Grigg RE, Inman M, Packham G Preparation of N-(2-aminophenyl)benzamide derivatives as histone deacetylase inhibitors. WO2013005049A1, 2013.
   Google Scholar
• Jacques V, Rusche JR Preparation of N-aminoaryl indazolamides as HDAC inhibitors. WO2014143666A1, 2014.
   Google Scholar
• Mazitschek R, Ghosh B, Hendricks JA, et al. Photoswitchable HDAC inhibitors. WO2014160221A1, 2014.
   Google Scholar
• Van Duzer JH, Golonzhka O, Jarpe MB Preparation of quinoline derivatives as HDAC1/2 inhibitors for the treatment of neurodegenerative and/or cognitive disorders. WO2017136451A1, 2017.
   Google Scholar
• Cheng Y-Q, Hossain MM, Steeber D, et al. Design and preparation of novel HDAC inhibitors and their use for treating cancers and neurological disorders. WO2017039726A1, 2017.
   Google Scholar
• Giannini G, Cabri W, Battistuzzi G, et al. Preparation of phenylcarbamoylhexanethiol derivatives bearing lactams as potent HDAC inhibitors for treatment of cancer. WO2013041480A1, 2013.
   Google Scholar
• Kozikowski A, Vallerini GP, Segretti M, et al. Bicyclic and tricyclic cap bearing mercaptoacetamide derivatives as histone deacetylase inhibitors. WO2017053360A1, 2017.
   Google Scholar
• Tillekeratne VLM, Almaliti J, Al-Hamashi A, et al. Preparation of largazole analog HDAC inhibitors as anti-cancer agents. WO2015175770A1, 2015.
   Google Scholar
• Meyer-Almes F-J, Meyners C, Kleinschek A, et al. Pyrimido[1,2-c][1,3]benzothiazin-6-imines and imidazo[1,2-c][1,3]benzothiazin-6-imines as selective HDAC8 inhibitors and their preparation. WO2017077008A1, 2017.
   Google Scholar
• Wright DL, Anderson AC, Van Heyst M, et al. Preparation of tropolone derivatives for use as histone deacetylase (HDAC) inhibitors. WO2013192554A1, 2013.
   Google Scholar
• Altamura S, Bresciani A, Breveglieri G, et al. Heterocyclic compounds useful in the treatment of disorders that are ameliorated by inhibition of HDAC. WO2014023754A1, 2014.
   Google Scholar
• Dominguez C, Maillard MC, Haughan AF, et al. Preparation of N-substituted oxadiazolylbenzamides as histone deacetylase inhibitors and compositions therof, for treatment of neurodegenerative diseases. WO2016179554A1, 2016.
   Google Scholar
• Dominguez C, Maillard MC, Breccia P, et al. Preparation of N-substituted oxadiazolylbenzamides as histone deacetylase inhibitors and compositions thereof, for treatment of neurodegenerative diseases. WO2016179550A1, 2016.
   Google Scholar
• Kaieda A, Toyofuku M, Daini M, et al. Oxadiazolyl-substituted heterocyclic compounds as HDAC inhibitors and their preparation. US20170015655A1, 2017.
   Google Scholar
• Balunas MJ, Pavlik CM, Gerwick WH Santacruzamate and analogs as Histone Deacetylase (HDAC) inhibitors. WO2014018913A2, 2014.
   Google Scholar
• Eilertsen KJ, Rim JS, Staszkiewicz J Small molecule inhibitors of histone deacetylase for treating cancer and reprogramming cells. WO2013059582A2, 2013.
   Google Scholar
• Montminy M Class IIa HDAC inhibitors for the treatment of bacterial infection. WO2015157500A1, 2015.
   Google Scholar
• Balasubramanian S Combination of ACK inhibitors and histone deacetylase (HDAC) inhibitors for the treatment of solid tumors. WO2015017812A1, 2015.
   Google Scholar
• Balasubramanian S, Mody TD Combinations of histone deacetylase inhibitor and pazopanib and uses thereof for treatment of cancer. WO2013123413A2, 2013.
   Google Scholar
• Graef T, Hsu SJ Treatment of cancer using HDAC inhibitors such as abexinostat and immunotherapy with immune checkpoint inhibitors. WO2017053823A1, 2017.
   Google Scholar
• Walter RB, Subklewe M, Krupka C Combination of epigenetic factors and bispecific factors targeting CD33 and CD3 in the treatment of myeloid leukemia. WO2015036583A2, 2015.
   Google Scholar
• Cosenza M, Pozzi S Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma. WO2016087950A1, 2016.
   Google Scholar
• Quayle SN, Jones SS, Anderson KC, et al. Combinations of histone deacetylase inhibitors and immunomodulatory drugs. WO2015054175A1, 2015.
   Google Scholar
• Quayle SN, Jones SS Combinations of histone deacetylase inhibitors and immunomodulatory drugs. US20150150871A1, 2015.
   Google Scholar
• Quayle SN, Shearstone JR Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs. WO2017143237A1, 2017.
   Google Scholar
• Quayle NS, Jones SS. Combinations of histone deacetylase inhibitors and immunomodulatory drugs. WO2015084905, 2015.
   Google Scholar
• Quayle SN, Jones SS, Sotomayor EM, et al. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating non-hodgkin’s lymphoma. WO2015054197A1, 2015.
   Google Scholar
• Quayle SN, Jones SS HDAC inhibitors, alone or in combination with PI3K inhibitors, for treating non-hodgkin’s lymphoma. WO2015054355A1, 2015.
   Google Scholar
• Stucchi AF, Cassidy M Histone deacetylase (HDAC) inhibitors for treatment of post-surgical adhesions. WO2013063435A1, 2013.
   Google Scholar
• Chen C-S, Bekaii-Saab T, Guttridge D, et al. Histone deacetylase inhibitors for suppressing cancer-related cachexia. WO2015077353A1, 2015.
   Google Scholar
• Hofland H, Mooser VE, Song K, et al. Method of treating. WO2013181487A2, 2013.
   Google Scholar
• Willis M, Bultman S Methods for treatment of heart failure using histone deacetylase inhibitors and histone acetyltransferase activators for increased expression of Brg1 and/or Brm genes. WO2016164482A1, 2016.
   Google Scholar
• Payet-Bornet D, Nadel B, Loosveld M, et al. Methods of treating T-cell acute lymphoblastic leukemias using BET bromodomain inhibitors and histone deacetylase (HDAC) inhibitors. WO2015144636A1, 2015.
   Google Scholar
• Pili R Use of histone deacetylase inhibitors for enhancing immunotherapies. WO2017132536A1, 2017.
   Google Scholar
• Ghosh S, Guerriero J, Kruidenier L, et al. Methods of use of a class IIa HDAC inhibitor. WO2017112838A1, 2017.
   Google Scholar
• Dent P, Zukiwski A, Proniuk S Enhancing the anti-tumor, anti-viral, and anti-protozoan effects of 2-amino-n-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide (OSU-03012) and other pharmaceutical drugs. WO2016069854A1, 2016.
   Google Scholar
• Tamang DL, Jones SS, Min C, et al. Treatment of leukemia with histone deacetylase inhibitors. WO2016007423A1, 2016.
   Google Scholar
• Tamang DL, Jones SS, Yang M Treatment of neuroblastoma with histone deacetylase inhibitors. WO2016168647A1, 2016.
   Google Scholar
• Tamang DL, Yang M, Jones SS Preparation of pyrimidine carboxamide derivatives as histone deacetylase inhibitors useful in combination therapy of breast cancer. US20150099744A1, 2015.
   Google Scholar
• Sierra Jimenez A, Oliva Miguel B, Muixi L Treatment of brain metastasis from cancer. WO2014180882A2, 2014.
   Google Scholar
• Volpe JM Treatment of latent HIV infection. WO2013165592A1, 2013.
   Google Scholar
• Hermant P, Bosc D, Piveteau C, et al. Controlling plasma stability of hydroxamic acids: a MedChem toolbox. J Med Chem. 2017;60(21):9067–9089.
   PubMed Web of Science ®Google Scholar
• Alzoubi KH, Khabour OF, Jaber AG, et al. Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage. Cytotechnology. 2014;66(3):449–455.
   PubMed Web of Science ®Google Scholar
• Farkas E, Katz Y, Bhusare S, et al. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem. 2004;9(3):307–315.
   PubMed Web of Science ®Google Scholar
• Reiter LA, Robinson RP, McClure KF, et al. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg Med Chem Lett. 2004;14(13):3389–3395.
   PubMed Web of Science ®Google Scholar
• Li Y, Woster PM. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. Med Chem Commun. 2015;6(4):613–618.
   Google Scholar
• McClure JJ, Zhang C, Inks ES, et al. Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia. J Med Chem. 2016;59(21):9942–9959.
   PubMed Web of Science ®Google Scholar
• HardingRJ, Ferreira De FreitasR, CollinsP, et al.Small molecule antagonists of the interaction between the histone deacetylase 6 zinc-finger domain and ubiquitin. J Med Chem. 2017;60(21):9090–9096.
   PubMed Web of Science ®Google Scholar